- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00505063
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center 1275 York Avenue
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be < or less 18 years of age at cancer diagnosis
Patient must be 3 to 24months following completion of chemotherapy for malignant disease.
- For patients <12 months following completion of therapy, CR must be documented within 3 months of enrollment.
- For patients >12 months, CR must be documented at approximately 12 months and then only as clinically indicated
i. For patients with leukemia: bone marrow aspirate defined as <5% blasts, absence of cytogenetic abnormality by FISH or karyotype (if applicable) and no evidence of CSF involvement (if applicable) ii. For patients with solid tumors remission will be determined by appropriate radiologic scans, and other tests, including bone marrow aspirate and biopsies demonstrating absence of extrinsic cells and absence of specific FISH or cytogenetic abnormality (if applicable), iii. For patients with lymphoma, remission will be determined by bone marrow aspirate and biopsy, radiologic scans and other tests. Bone marrow will show <5% blasts, absence of cytogenetic abnormality by FISH or karyotype (if applicable), and flow cytometry (if lymphoma specific marker present) and absence of CNS disease by spinal fluid (if applicable)
- Patient may be of either gender and of any ethnic background
- Patients or their guardians must be able to understand the nature and risk of the proposed study and be able to sign consent.
Exclusion Criteria:
- Karnofsky score <70%.
- Female patients who are pregnant or lactating.
- Patients who have received an autologous or allogeneic HCT.
- Active uncontrolled bacterial or fungal infection.
- Patients who have a history of previous allergic reaction to vaccinations currently recommended by the ACIP.
- Patients on any immunosuppressive drugs.
- HIV-1,2 sero-positive patients.
- Patients or guardians not signing informed consent.
- Patients with prior allergic reaction to any vaccine component or to latex.
- Patients who have received Rituximab.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: A
Immunization Schedule patients <7 years.
|
Other Names:
|
Other: B
Immunization Schedule patients > or = to 7 years and <11 years of age
|
Other Names:
|
Other: C
Immunization Schedule patients > or = to 11 years of age
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To prospectively determine the response rate and duration of protective titers following revaccination with routine childhood immunizations in pediatric survivors of childhood cancer.
Time Frame: conclusion of study
|
conclusion of study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine whether in vitro parameters of lymphoid reconstitution correlate with response and duration of response.
Time Frame: conclusion of study
|
conclusion of study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nancy Kernan, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-088
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Childhood Cancer
-
Australian & New Zealand Children's Haematology...Medical Research Future Fund; Minderoo Foundation; Children's Cancer Institute...RecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
Sydney Children's Hospitals NetworkGerman Cancer Research Center; Australian & New Zealand Children's Haematology... and other collaboratorsRecruitingChildhood Cancer | Relapsed Cancer | Refractory Cancer | Childhood Leukemia | Childhood Solid Tumor | Childhood Brain TumorAustralia
-
University of Colorado, DenverRecruitingCancer | Childhood CancerUnited States
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
Wake Forest University Health SciencesTerminated
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Pernille BidstrupOdense University Hospital; Aarhus University Hospital; Aarhus University Hospital... and other collaboratorsCompleted
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Children's Cancer Group, ChinaShanghai Children's Medical Center; Shanghai Municipal Center for Disease Prevention...Recruiting
-
St. Jude Children's Research HospitalRecruiting
Clinical Trials on Immunization Schedule patients <7 years.
-
SanofiCompletedGaucher's DiseaseUnited States
-
Jiangsu Province Centers for Disease Control and...Academy of Military Medical Sciences,Academy of Military Sciences,PLA ZHONGYIANKE...Recruiting
-
PETHEMA FoundationCompleted
-
Centre Hospitalier Universitaire de NiceCompletedPatient Who is Requiring Bilateral Sinus Floor Elevation and Necessity of Dental SurgeryFrance
-
Assistance Publique - Hôpitaux de ParisCompletedSpinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia, Autosomal Recessive 3 | Episodic Ataxia, Type 7France
-
China Academy of Chinese Medical SciencesZhengzhou Children's Hospital, China; Qilu Children's Hospital of Shandong... and other collaboratorsUnknownUpper Respiratory Tract Infection | Acute Tracheobronchitis
-
Quaid-e-Azam UniversityHealth Services Academy, Islamabad, Pakistan; Medical Research Council, PakistanCompleted
-
Andros Day Surgery ClinicCompleted
-
West Kazakhstan Medical UniversityRecruitingOrnithine Transcarbamylase Deficiency | Biotinidase Deficiency | Citrullinemia | Glutaric Acidemia Type II | Argininosuccinic Aciduria | Maple Syrup Urine Disease | Primary Carnitine Deficiency | Homocystinuria | Carnitine Palmitoyltransferase II Deficiency | Arginase Deficiency | Very Long-chain Acyl-CoA... and other conditionsKazakhstan
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation Trust; Great Ormond Street Hospital...RecruitingCardiovascular Diseases | Inherited Cardiac ConditionsUnited Kingdom